Changes in the central ANF-system of renovascular hypertensive rats  by Bahner, Udo et al.
Kidney international, Vol. 39 (1991), PP. 33—38
Changes in the central ANF-system of renovascular
hypertensive rats
UDO BAHNER, HELMUT GEIGER, MIKLOS PALKOVITS, DETLEV GANTEN, BURKHARD KLOTZ,
and AUGUST HEIDLAND
Medical Clinic of the University, Division of Nephrology, Wurzburg, Federal Republic of Germany; First Department of Anatomy,
Semmelweis University, Medical School, Budapest, Hungary; and Department of Pharmacology, University of Heidelberg, Heidelberg,
Federal Republic of Germany
Changes in the central ANF-system of renovascular hypertensive rats.
The central atrial natriuretic peptides (ANF)-system was investigated in
volume-dependent one-kidney, one-clip (1K1C) and renin-dependent
two-kidney, one-clip (2K IC) renovascular hypertensive rats by radio-
immunological measurement of ANF concentration in 18 selected brain
areas. Significant changes were found in nine brain areas of IK1C and
in eight brain areas of 2KIC hypertensive rats. Except unidirectional
changes in the organum vasculosum laminae terminalis and the su-
praoptic nucleus, ANF concentration was changed in the opposite
direction in all other brain areas, with an activation of the central ANF
system in 1K1C and an inhibition in 2KIC hypertension. The localiza-
tion of the alterations (circumventricular organs, anteroventral third
ventricle region, hypothalamo hypophyseal system, brain stem) implies
major differences in the central regulation of blood pressure and
electrolyte and fluid homeostasis between these two models. The
activation of the central ANF system in 1K1C hypertension may be a
compensatory mechanism to prevent further increments in blood pres-
sure and plasma volume. In contrast, the depression of the central ANF
system in 2K1C hypertension may promote the elevation of the blood
pressure.
Since Goldblatt et al [1] demonstrated the development of
arterialhypertension following renal ischemia, the pathogenesis
of renovascular hypertension has been intensively investigated.
However, the mechanism of the hypertension in renal artery
stenosis is still not completely understood. Clipping of one renal
artery regularly induces hypertension, but there are differences
between the two-kidney, one-clip (2K1C) model, in which the
contralateral kidney is untouched, and the one-kidney, one-clip
(1K1C) model, in which the contralateral kidney is removed.
The 2K1C model seems to be dependent on the renin-angioten-
sin system, while the 1K1C model is suggested to be volume
expanded [2—5].
There is an increasing number of indications that the atrial
natriuretic factor (ANF), a peptide hormone that is intimately
involved in the regulation of renal and cardiovascular homeo-
stasis [6—8], may play an important role is the pathomechanism
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of renovascular hypertension. In 1K1C rats plasma ANF levels
are positively correlated with blood pressure and negatively
correlated with ANF concentration in the left atrium [9].
Additional infusion of synthetic ANF results in a reduction of
blood pressure and increased diuresis and natriuresis in lKlC
rats [10]. Unclipping of the remaining kidney is accompanied by
a reversal of hypertension, which might be partially due to the
still higher plasma ANF levels [9]. Based on these findings, it
was suggested that the increased plasma ANF level in 1K1C
hypertension reflects a compensatory mechanism preventing
further increments in blood pressure and plasma volume. In
2K1C rats plasma ANF level is unchanged, but chronic admin-
istration of synthetic ANF also decreases blood pressure in
renin-dependent 2K1C hypertension [11]. The hypotensive ef-
fect of ANF in this model may be related to the inhibition of
renin release and the consequent decrease of plasma angioten-
sin II and aldosterone levels [12].
However, the mechanisms underlying the shifting pattern of
hemodynamic and humoral events in the various stages and
different forms of renal hypertension may not only be localized
in the periphery but may be combined with regulatory mecha-
nisms in the central nervous system. Thus, it was shown that
1K 1 C hypertension is associated with an increased activity of
the sympathetic nervous system [13,14], and that ablation of the
anteroventral third ventricle (AV3V) region prevents the devel-
opment of 2K1C hypertension [15,16}. Since the central ANF
system is known to be important for the regulation of electro-
lyte and fluid homeostasis and blood pressure [17—21], it may
also be involved in the pathophysiology of renovascular hyper-
tension. To elucidate this question, we have investigated the
central ANF system in the early maintenance phase of 1K1C
and 2K1C renovascular hypertension, when differences in the
pathological disorders could be expected. For this purpose, the
concentration of ANF was measured radioimmunologically in
18 selected brain areas of 1K1C and 2K1C hypertensive rats
and compared with the respective controls. Previous studies
have shown that the concentration of ANF in specific brain
areas is a sensitive parameter for alterations in the electrolyte
and fluid homeostasis and blood pressure [22—24].
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Methods
Protocol
Renovascular hypertension was produced in male Sprague-
Dawley rats (Charles River Wega GmbH, Sulzfeld, FRG;
weight 80 to 100 g; age 35 to 40 days) under sodium pentobar-
bital anesthesia (60 mg/kg body wt i.p.) by partial constriction
of the left renal artery with a silver clamp of 0.20 mm internal
diameter. In the 1K1C hypertension group the contralateral
kidney was removed simultaneously, whereas it was left un-
touched in the 2KIC hypertension group. Animals subjected to
sham operation, in which a silver clamp was temporarily placed
around the left renal artery and then taken away and the right
kidney was removed (1K1C control group) or left untouched
(2K1C control group), served as normotensive controls. The
animals were housed at a constant room temperature of 22° 1°
C and a humidity of 60% 4%, with illumination from 6.00 a.m.
to 6.00 p.m. Systolic blood pressure was measured indirectly
once a week by means of the tail cuff technique. The criterion
for classifying renovascular hypertensive and sham operated
animals were as follows: clipped animals having a systolic blood
pressure higher than or equal to 160 mm Hg (about 70% of all
clipped animals) were classified as renovascular hypertensive
rats; all animals selected for the 2K1C hypertension group had
to have a four fold increased plasma renin activity; sham
operated animals having a systolic blood pressure less than or
equal to 120 mm Hg (about 90% of all sham operated animals)
were classified as normotensive.
Determination of blood parameters
The blood parameters were determined separately in 10
animals per experimental group. The animals were chosen
randomly and moved to a quiet room. One at a time they were
transferred to an adjacent room.
For determination of hematocrit, plasma osmolality, serum
sodium, potassium and chloride concentration blood was col-
lected by puncture of the aorta under sodium pentobarbital
anesthesia (60 mg/kg body wt i.p.). Hematocrit was determined
by an automatic analyzer (ELT 8, Fa. Moltronic, Heidelberg,
FRG), plasma osmolality by freezing point depression (Osmo-
mat, Fa. Gonotec, Berlin, FRG), serum sodium and potassium
by flame photometry (AFM 2, Eppendorf Co., Hamburg, FRG)
and chloride by mercurymetry (Chiorimeter, Eppendorf Co.,
Hamburg, FRG).
For determination of plasma renin activity (PRA) and angio-
tensin II (Ang II) concentration rats were rapidly anesthetized
with ether, a laparatomy performed, and blood collected from
the abdominal aorta. The interval between the beginning of the
exposure to ether and the end of the blood withdrawal never
exceeded 150 seconds. Blood was collected into prechilled
(4°C) polypropylene tubes, which contained 5% of a solution of
125 mri EDTA for determination of PRA or 5% of a solution of
125 msi EDTA and 26 mi orthophenantroline for determination
of Ang II concentration. After centrifugation (6000 g, 10 mm, at
4°C) plasma was stored at —20°C until assay. PRA was deter-
mined by radioimmunological measurement of generated angio-
tensin I [25] and Ang II was measured by direct radioimmuno-
assay in unextracted plasma [261.
Plasma aldosterone concentration was measured in heparin-
ized, unextracted plasma by a commercial aldosterone radio-
immunoassay (Biermann Diagnostica, Bad Nauheim, FRG).
Plasma arginine vasopressin concentration was measured
after extraction from plasma by radioimmunoassay as described
elsewhere [27].
For determination of plasma norepinephrine concentration
blood was collected during the first 3 seconds after rapid
decapitation into prechilled (4°C) polypropylene tubes contain-
ing EDTA. The measurement was performed by high-pressure
liquid chromatography using a Beckman 114 M pump and a
Chromatopak C-18 column. The samples were eluted in an
isocratic system with a 0.06 M phosphate buffer at a flow rate of
0.5 mI/mm. The detection was carried out electrochemically at
+ 650 mY towards an Ag/AgCI electrode [28].
For determination of plasma ANF concentration, blood was
taken from the aorta, collected in polypropylene tubes contain-
ing 500 KIU aprotinin (Trasy1ol', Bayer AG, Leverkusen,
FRG), and immediately centrifuged (2.000 g, 10 mm, at 4°C).
The plasma was stored at —70°C until assay. ANF was ex-
tracted from plasma according to the method of Larose et al [29]
modified in some details. Plasma sample (1 ml) acidified to pH
3 to 4 with 2 N HCL was applied to a Sep Pak Cl8 reverse-phase
octadodecyl silane cartridge column (Water Associates, Mil-
ford, Massachusetts, USA) that had been activated previously
with 100% methanol (10 ml) followed by 5% acetic acid (10 ml).
After washing with trifluoracetic acid (TFA, 3 X 5 ml), the
peptide was eluted with a mixture of 60% acetonitrile in 0.1%
TFA (2 ml). The eluates were evaporated to dryness with
nitrogen, and the residue was reconstituted with 1 ml of RIA
buffer (50 m potassium phosphate buffer, pH 7,4, containing
0.1% BSA, 0.02 NaN3, 50mM NaC1, 0.1% Triton X-100, 50 LM
phenylmethylsulfonyl fluoride and 10 pM aprotinin) for ANF
determination by radioimmunoassay.
Tissue dissection and extraction ofbrain ANF
The animals were decapitated between 8.00 and 10.00 a.m.,
brains were quickly removed and frozen on dry ice. Serial
coronal sections with 300 m thickness were cut in a cryostat
on —10°C and 18 brain regions (Table 2) were removed by the
micropunch technique [301. The brain regions represented those
functional systems which were mainly involved in the regula-
tion of electrolyte and fluid homeostasis and blood pressure.
Tissue pellets of identical brain nuclei of four animals were
pooled, and six assay sets per group were formed (4 x 24 rats).
The samples were collected in 1.5 ml conical Eppendorf tubes
containing 60 tl 0.1 N HCL and put in a boiling water bath for
10 minutes. After addition of 100 pi RIA-buffer the samples
were homogenized and 20 isl aliquots of the homogenates were
removed for protein determination according to Lowry et al
[311. The remaining sample was centrifuged at 2000 g for 15
minutes at 4°C and l0)d of the supernatant fluid were used for
ANF determination by radioimmunoassay.
Measurement of plasma ANF and brain ANF concentration
For determination of plasma ANF and brain ANF concentra-
tion a commercial radioimmunoassay kit was used (Peninsula
Labs., INC, Belmont, California, USA; RIK 8798). The rabbit
antihuman ANF (99-126) antiserum of this kit cross reacts with
the different atrial natriuretic peptides as follows: 100% with
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Table 1. Characteristics of IKlC and 2KIC renovascular hypertensive rats and their control rats (mean 5EM)
1KIC 2K1C
control 1KIC control 2K1C
No. 10 10 10 10
Body weight g 262.0 8.5 246.5 9.5 266.0 8.5 232.5 7.0
Systolic blood pressure mm Hg 112.5 3.5 178.0 4•5C 116.5 3.5 175.0 5.0°
Water intake % of body wt 15.5 1.5 10.8 2.6a 15.0 0.5 23.0 l.2
Urine volume % of body wt 7.3 0.9 5.3 0.6 8.0 0.4 11.0 l.3a
Hematocrit % 41.7 0.5 38.1 0.4a 42.1 0.4 46.1 o.4
Plasma sodium concentration mmoi/liter 147.7 1.0 141.2 16b 150.8 0.6 148.1 1.4
Plasma potassium conc. mmoi/liter 4.4 0.1 4.5 0.2 4.5 0.2 4.4 0.2
Plasma chloride conc. mmol/liter 99.5 1.3 98.0 0.4 103.7 0.7 101.7 1.5
Plasma osmolality mOsm/kg water 315.4 1.4 302.4 2.0" 318.6 2.4 316.2 1.9
Plasma renin activity ng Ang I/mI/hr 1.5 0.2 1.4 0.2 1.9 0.4 9.8 0.6°
Plasma angiotensin II conc.fmol/ml
Plasma aldosterone conc.fmol/mi
152.3 23.1
81.0 19.7
147.1 16.2
67.2 16.2
150.5 21.0
94.5 20.2
956.5 935C
486.0 81.0"
Plasma norepinephrine conc. pmoi/liter
Plasma arginine vasopressin conc. pg/mi
1.0 0.3
1.0 0.1
3.5 0.4"
1.1 0.2
1.3 0.2
1.1 0.1
1.4 0.3
2.6 04b
Plasma ANF concentration pg/mi 7.2 0.8 29.6 2.5C 8.0 1.3 12.6 1.8
a p < oo5, b p < 0.01, P < 0.001, significant difference from the renovascular hypertensive rats to their respective control rats
human ANF (99-126), rat ANF (99-126) and rat ANF (102-126),
90% with rat ANF (101-126), 88% with rat ANF (103-126), 57%
with ANF (108-126), 50% with rat ANF (111-126), 27% with rat
ANF (103-125), 10% with rat ANF (102-125) and 3% with rat
ANF (103-123). The ANF antiserum does not cross react with
somatostatin, oxytocin, arginine8-vasopressin and brain natri-
uretic polypeptide porcine (BNP). In conclusion, the antiserum
recognizes nearly completely the active forms of ANF as well in
the plasma (rat ANF (99-126)) [7,321 as in the brain (rat ANF
(102-126) and rat ANF (103-126)) [33,34].
The reconstituted plasma extracts (100 pd), respectively, the
brain extracts (100 d) were incubated with the same volume of
the antiserum. Synthetic human ANF (99-126) ranging from ito
128 pg/tube was incubated as standard. After incubation for 24
hours at 4°C, 100 sl of the ANF tracer '2J-human ANF (99-126)
was added. After again 24 hours incubation at 4°C, goat
anti-rabbit IgG serum and normal rabbit serum (100 pJ, dis-
solved in RIA buffer) were added and the mixture was incu-
bated at room temperature for two hours. Then 500 .d RIA
buffer was added, the contents were vortex mixed and then
centrifuged (2000 g, 20 mm, at 20°C). After centrifugation the
supernatants were aspirated and the precipitants were counted
in a gamma counter. The sensitivity of the assay was 1.5
pg/tube. The recovery of added ANF standard was 78.7 3.3%
(mean SEM, N = 6) and the intraassay and interassay
variations were 9% and 14%, respectively. Serial dilutions of
plasma and brain extracts showed parallelism to the synthetic
ANF standards.
Statistical analysis
The results are expressed as mean SEM. Statistical signif-
icance was tested by the Student's t-test. Differences at the 95%
level were considered significant.
Results
Animal characteristics
Data are summarized in Table 1. Five weeks after surgery the
mean blood pressure was 178 mm Hg in 1K1C rats and 175 mm
Hg in 2K1C rats; the development of blood pressure is shown in
Figure 1. In 1K1C hypertensive rats there was a significant
decrease in water intake, hematocrit, plasma sodium concen-
tration and plasma osmolality; plasma ANF and plasma norepi-
nephrine concentrations were significantly increased. In con-
trast, 2K1C-hypertensive rats showed a significant increase in
water intake, urine volume and hematocrit. The measurement
of different components of the renin-angiotensin-aldosterone
system revealed an expressed stimulation of this system with an
about fivefold increase of plasma renin activity, plasma angio-
tensin II and plasma aldosterone concentration. Furthermore,
plasma arginine vasopressin concentration was significantly
increased.
ANF concentration in spec/lc brain areas
The comparison of ANF concentrations in renovascular
hypertensive rats with their normotensive control rats showed
significant differences in nine brain areas of 1K 1 C hypertensive
rats and in eight brain areas of 2K1C hypertensive rats (Table
2). In 1K1C hypertensive rats ANF concentration was signifi-
cantly decreased only in the organum vasculosum laminae
terminalis (OVLT) (28% of control). In all other brain areas
with changes ANF concentration was significantly increased.
Very pronounced elevations were found in the subfornical
organ (211%), the supraoptic (244%) and paraventricular (172%)
nuclei, the arcuate nucleus (245%), the median eminence
(231%), the periventricular preoptic nucleus (169%) and the
locus coeruleus (206%). The increase in the dorsal raphe
nucleus (134%) was just moderate. In contrast, in 2K1C hyper-
tensive rats ANF concentrations were increased only in the
supraoptic nucleus (202%) and the medial amygdaloid nucleus
(179%), whereas a significant decrease was found in the cere-
bral cortex (52%), the OVLT (36%), the periventricular preop-
tic nucleus (33%), the nucleus interstitialis striae terminalis
(NIST) (59%), the median eminence (60%) and the medial
forebrain bundle (69%).
Discussion
Present data confirm that there are differences in the patho-
genesis of 1K1C and 2K1C hypertension. In 1K1C rats we have
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Table 2. Concentrations of ANF in selected brain areas of 1K1C and 2K1C renal hypertensive rats and their control rats (pg ANF/mg protein;
mean SEM)
Brain area
1K1C
control IK1C
2K1C
control 2K1C
Cerebral cortex 46.2 7.8 42.4 6.1 42.7 4.5 22,2 2.1k'
Org. vasc. lam, term. 83.0 7.0 23.0 l.7c 107.1 3.7 38.7 6.5
Subfornical organ 73.6 6.8 155.6 87b 76.6 15.8 86.0 19.8
Periventr. preopt. nucl. 337.5 16.0 570.8 75.8a 400.6 47.3 134.2 l8,3c
Medial preopt. nucl. 237.8 9.4 235.0 20.0 219.6 35.3 173.1 12.8
NIST 140.6 20.9 214.8 21.8 123.7 13.3 73.3 7,2b
Periventr. hypoth. nucl. 256.1 50.3 182.2 26.7 190.6 22.6 173.6 9.9
Supraoptic nucl. 44.2 8.1 107.8 9.0" 47.9 5.9 96.8 10.4"
Paraventricular nucl. 146.0 13.1 251.7 15.7" 153.9 9.2 177.0 19.1
Arcuate nucl. 125.8 12.8 308.6 42.4c 109.1 16.3 116.5 19,6
Median eminence 175.9 15.3 406.0 69.2" 152.5 13.5 91.0 77l
Perifornical nucl. 99.5 16.6 106.1 23.3 77.9 7.2 95.4 9.6
Median forebrain bundle 62.6 6.6 49.0 6.2 61.4 4.0 42.4 4.5a
Medial amygd. nucl. 42.3 4.0 63.7 12.1 31.3 4.3 56.2 9,4a
Dorsal raphe nuci. 90.6 12.2 121.2 8.7a 104.3 14.9 115.0 24.7
Tegmentum pontis 118.6 21.6 70.3 11.6 95.4 10.0 83.9 6.3
Locus coeruleus 62.9 9.4 129.8 799 3.8 82.8 3.3
NucI. tractus solitarii 74.3 5.6 65.0 8.3 54.2 4.1 51.6 3.8
"P < 0.05, < 0.01, ' P < 0.001, significant difference from the renovascular hypertensive rats to their respective control rats
found a normal plasma renin activity but a significantly in-
creased plasma ANF level, which might be elevated in response
to the augmented plasma volume in these animals. In contrast,
the hypertension in our 2KIC model seems to be clearly renin
dependent, since we have found an almost fivefold increase of
plasma-renin-activity, plasma angiotension II and plasma aldo-
sterone concentration. The unchanged plasma ANF level and
the significantly increased water intake tell against a relevant
volume load in these animals.
The determination of ANF concentration in specific brain
areas shows differential changes in 1K1C and 2K1C hyperten-
sive rats. Except the unidirectional changes in the organum
vasculosum laminae terminalis and in the supraoptic nucleus,
ANF is changed in the opposite direction in all other brain
areas, with an activation of the central ANF system in volume-
dependent 1K1C hypertension and an inhibition in renin-depen-
dent 2K1C hypertension. In both models significant alterations
were found in the circumventricular organs, in areas of the
anteroventral third ventricle (AV3V) region and in the hypo-
thalamohypophyseal system. In 1K1C hypertensive rats ANF
was furthermore elevated in brain areas which are involved in
the regulation of the sympathetic nervous system.
Of special interest are the alterations in the two investigated
circumventricular organs, the subfornical organ (SF0) and the
organum vasculosum laminae terminalis (OVLT). These brain
areas lack a blood brain barrier and are exposed to changes in
levels of circulating peptides such as ANF and may therefore
represent the brain sites of action for circulating ANF. The SF0
has long been implicated in the central regulation of electrolyte
and fluid homeostasis and blood pressure [35—371. In addition to
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very high numbers of ANF receptors it contains also very high
concentrations of angiotensin II (Ang II) receptors and has been
shown to be the main brain target site for circulating Ang 11138].
Stimulation of Ang II receptors results in increased thirst,
increased vasopressin secretion and increased blood pressure
[391. Since these actions are opposed by ANF [17—20,40] a local
antagonism between these two peptides was postulated to exist
in the SF0. In this regard, it is conceivable that the SF0 might
also be involved in the pathomechanism of renovascular hyper-
tension. The increased binding of ANF in the SF0 of 1K1C
hypertensive rats could be a mechanism by which volume
overload is signalled to intracerebral regulatory systems. In
contrast, the unchanged ANF concentration in the SF0 of
2K1C rats indicates that an imbalance between ANF and A II
might exist there in these rats, which could be transferred to
structures inside the blood brain barrier.
The OVLT contains not only ANF receptors, but also large
numbers of ANF-immunoreactive nerve terminals and cell
bodies. The coexistance of ANF receptors and ANF containing
terminals outside the blood brain barrier suggests the possibility
of an intimate connection between the peripheral and the
central peptide system in the OVLT. Topographically and
functionally, the OVLT belongs to the so-called anteroventral
third ventricle (AV3V) region [41], which includes additionally
the preoptic and hypothalamic periventricular nuclei and a part
of the medial preoptic nucleus. This region incorporates the
largest accumulation of ANF containing cells in the brain [21,
34]. It is sensitive to osmotic stimuli [41] and known to
integrate, at a central level, mechanisms which modulate com-
plex homeostatic systems, such as those associated with body
fluid and electrolyte balance as well as cardiovascular regula-
tion [41,42]. The importance of this brain region for the devel-
opment of renovascular [15,16], Dahl [43] and deoxycorticos-
terone acetate salt [15] hypertension is well known. The
changes of ANF concentration in the AV3V region of our
models imply a special role for ANF mediated mechanisms at this
level. In the OVLT, ANF is significantly decreased in both lKlC
and 2K1C hypertensive rats. Since a similar decrease was also
found in spontaneously hypertensive rats [22], we suggest that
ANF is decreased there as a consequence of the raised blood
pressure. However, the mechanism remains to be elucidated.
Significant changes of ANF concentration have also been
found in the hypothalamic supraoptic (SON) and paraventricu-
lar nuclei (PVN), where vasopressin is produced. On the basis
of neuroanatomical and electrophysiological studies [19,44—48]
it was suggested that vasopressin secretion is integrated by a
regulatory unit which is composed of structures in the SF0, the
AV3V region, the SON and PVN and uses Ang II and ANF as
antagonistic neurotransmitters. The changes of ANF concen-
tration in this regulatory unit indicate an altered influence on
vasopressin secretion in both models of renovascular hyperten-
sion. But the significantly increased ANF level in 1K1C and
2K1C rats may be caused by different mechanisms. In volume
loaded 1K1C rats ANF may be elevated there to inhibit
vasopressin secretion. However, the unchanged plasma vaso-
pressin concentration indicates that vasopressin secretion may
still be too high for the state of volume dependent hypertension.
In renin-dependent 2K1C rats ANF may be increased there to
counteract the Ang Il-stimulated vasopressin secretion. Inter-
estingly, ANF in the PVN is only increased in lKlC rats. This
may be explained by the different functional activity of the PVN
and SON. While vasopressin and oxytocin secretion is domi-
nant in the SON, the function of the PVN is more complex.
Only the magnocellular subdivision of the PVN is engaged in
vasopressin and oxytocin secretion, but the parvocellular sub-
division contains several other neurotransmitters and neurohor-
mones which are mainly involved in the regulation of the
anterior pituitary gland [49]. Furthermore, cells in the PVN are
integrated in a neural network with structures in the brain stem
and the spinal cord and thereby involved in the regulation of
blood pressure [50]. The increased ANF content in the PVN of
1K1C rats might therefore be related with these functions.
In this context it is of interest, that in the locus coeruleus
ANF is increased only in 1K1C rats. The locus coeruleus is the
quantitatively most important noradrenergic cell group of the
brain and known to be involved in blood pressure regulation by
modulation of the sympathetic nervous activity. It was shown
that ANF can inhibit the increased sympathetic nervous activ-
ity in 1K 1C hypertensive rats [51]. Therefore, we conclude that
the increased ANF concentration in the locus coeruleus aims at
an inhibition of the sympathetic nervous activity at this level
and thereby counteracts the increased blood pressure. Interest-
ingly, ANF is also increased in the locus coeruleus of DOCA-
salt hypertensive rats; this form of hypertension is also volume
dependent [38].
In conclusion, the central ANF system is differentially acti-
vated in 1K1C and 2K1C renovascular hypertension. In 1K1C
hypertension, the activation of the central ANF system may be
a compensatory mechanism to prevent further increments in
blood pressure and plasma volume. In contrast, the depressed
activity of the central ANF system in 2K1C hypertension may
be a factor by which the elevation of blood pressure is promoted.
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